Skip to main content

Krystal Biotech, Inc. (KRYS)

Stock NASDAQ

$298.55

-1.44 (-0.48%)

Delayed quote.

Price history

Daily close
KRYS daily closing price, Nov 18, 2025 to Nov 17, 2026 Closed at $204.74 on Nov 18, 2025 and $298.55 on Nov 17, 2026, a change of +45.82%. Range $204.10 to $378.15.
Daily closes, Nov 18, 2025 to Nov 17, 2026 (251 trading days).
Start
$204.74
Latest close
$298.55
Period change
+45.82%
Period low
$204.10
Period high
$378.15

Key metrics

Market cap
$8.79B
Volume
18.2K
Average volume
355.5K
52-week range
$203.17 – $382.54
Beta
0.50
Last dividend
—
EPS (TTM)
$7.66
P/E ratio
38.98
Revenue (TTM)
$470.02M
Net income (TTM)
$225.17M
Total assets
$1.59B
Total debt
$8.59M
Cash and equivalents
$462.84M

Key financials (trailing twelve months).

Company profile

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
CEO
Krish S. Krishnan
Employees
295
Headquarters
Pittsburgh, PA, US
IPO date
2017-09-20

Financial statements

Annual, last 3 fiscal years. Most recent period first. Reported in USD.

Income statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Revenue$389.13M$290.51M$50.70M
Gross profit$360.36M$270.45M$47.60M
Operating income$161.29M$65.69M-$109.73M
EBITDA$196.02M$109.91M-$92.22M
Net income$204.83M$89.16M$10.93M
Diluted EPS$6.84$3.00$0.39
Balance sheet
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Cash and equivalents$496.30M$344.87M$358.33M
Total assets$1.33B$1.06B$818.36M
Total liabilities$114.23M$109.46M$39.71M
Total debt$9.34M$7.26M$8.09M
Shareholders’ equity$1.22B$946.38M$778.64M
Cash flow statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Operating cash flow$200.87M$123.42M-$88.80M
Capital expenditure-$11.95M-$4.24M-$11.80M
Free cash flow$188.91M$119.18M-$100.60M

Quarterly, last 6 quarters. Most recent period first. Reported in USD.

Income statement
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Revenue$127.34M$119.22M$116.36M$107.11M$97.80M$96.04M
Gross profit$119.78M$112.78M$110.03M$96.19M$92.14M$88.88M
Operating income$71.14M$58.42M$53.69M$44.44M$41.37M$39.31M
EBITDA$81.83M$67.64M$63.17M$39.61M$49.58M$48.32M
Net income$63.07M$54.77M$55.93M$51.40M$79.36M$38.33M
Diluted EPS$2.05$1.79$1.83$1.70$2.66$1.29
Balance sheet
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Cash and equivalents$462.84M$427.74M$501.31M$496.30M$392.60M$353.83M
Total assets$1.59B$1.50B$1.40B$1.33B$1.24B$1.14B
Total liabilities$150.47M$141.52M$120.24M$114.23M$102.22M$97.75M
Total debt$8.59M$8.85M$9.11M$9.34M$9.51M$9.68M
Shareholders’ equity$1.44B$1.36B$1.28B$1.22B$1.14B$1.04B
Cash flow statement
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Operating cash flow$91.25M$74.79M$80.38M$77.51M$39.66M$52.73M
Capital expenditure-$996.0K-$3.56M-$7.15M-$2.14M-$1.70M-$1.90M
Free cash flow$90.25M$71.22M$73.23M$75.37M$37.95M$50.83M